



9 July 2021

OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")

AbC-19™ rapid antibody test performance evaluation

Peer-reviewed performance evaluation and self-test user experience of AbC 19™

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner, welcoming the publication of two peer-reviewed studies conducted by Ulster University and involving AbC-19™, a lateral flow test for the [detection of neutralising IgG antibodies](#) to the full trimeric spike protein of the SARS-CoV-2 virus.

Highlights from the studies include:

- Excellent laboratory validation performance metrics for the AbC-19™ rapid test for SARS-CoV-2 spike protein IgG antibody detection and semi-quantitative correlation with laboratory ELISA methods assaying IgG antibodies to the spike protein of the SARS-CoV-2 virus.
- AbC-19™ showed sensitivity of 97.58% and specificity of 99.59% when using evaluation methods as defined by the MHRA for Target Product Profile of an antibody test.
- In addition, the study notes that IgG antibodies to the SARS-CoV-2 virus were detected 10 months after infection. Understanding the longevity of COVID-19 antibodies is important both immunologically and in helping to guide pandemic exit protocols.
- Positive user experience score from 1,544 participants who used AbC-19™ as a 'self-test'

Professor Chris Molloy, Independent chairman of the UK Rapid Test Consortium said: *"We are entering a phase of the pandemic where testing for immunity will become as or more important than testing for infection. Rapid, accurate immunity tests are therefore a critical tool for citizens and public health providers to embrace.*

"Development of multiple antibody tests, and semi-quantitative approaches will enhance this portfolio and enable the most rapid global recovery."

The UK-RTC press release can be read in full here:

<https://www.abc19.com/peer-reviewed-performance-evaluation-and-self-test-user-experience-of-abc-19/>

Contacts:

Omega Diagnostics Group PLC

Colin King, Chief Executive

Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

via Walbrook PR

finnCap Ltd

Geoff Nash/Edward Whiley (Corporate Finance)

Alice Lane (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus

Lianne Cawthorne

Tel: 020 7933 8780 or omega@walbrookpr.com

Mob: 07980 541 893

Mob: 07584 391 303